A number of compound series will result from Inimex' lead optimization program, which will permit development of a pipeline of distinct IDR products for a range of indications.
Inimex' first generation IDR products are short peptides suitable for parenteral, aerosol, or topical administration. An intravenous product formulation will be developed in the first instance, suitable for hospitalised patients who will usually have an intravenous line.
The lead first generation product candidates have the following drug profile:
- Efficacy in Animal Models
- Broad Spectrum
- Prophylactic and Therapeutic Activity
- Local and Systemic effects
- Flexibility for route of administration
- Complementary to antibiotics
-
- Favorable Safety Profile
- Commercially Realistic CMC
The Company also expects to identify second generation products suitable for oral administration utilizing proprietary assays and knowledge of structure-activity relationships resulting from the first generation drug selection programs.
A publication outlining the scientific background on IDR-1, a prototype IDR compound, was recently published in the journal Nature Biotechnology
(Vol. 25 No. 4). |
|
|
Product Profile